Serono Symposia International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so participants may form their own judgments, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement, nor a recommendation, on the part of Serono Symposia International Foundation. All presentations solely represent the independent views of the presenters/authors.

The following faculty indicated no significant commercial relationships and/or discussions of investigational or non- EMEA/FDA approved (off-label) uses of drugs:

Hartmut Wekerle

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non- EMEA/FDA approved (off-label) uses of drugs:

Frederik Barkhof: Declared receipt of honoraria or consultation fees from UCB, Schering, Sanofi-Aventis, Novartis, Roche. He declared also to be a member of UCB, Schering, Sanofi-Aventis, Novartis, Roche advisory boards, board of directors or other similar groups.

Giancarlo Comi: Declared receipt of honoraria and consultation fees from Serono Symposia International Foundation, Merck Serono, Novartis, Teva Pharmaceutical Industries Ltd, Sanofi-Aventis, Bayer Schering and Biogen Dompè.

Mark S. Freedman: Declared receipt of honoraria or consultation fees from Bayer, Biogen Idec, Merck Serono, Sanofi-Aventis, Eli-Lilly, Teva, Novartis, Genentech. He declared also to be a member of BioMS, Bayer, Sanofi-Aventis, Merck Serono and Novartis advisory boards.

Ralf Gold: Declared receipt of grants and contracts from Biogen, Teva, Bayer Schering and Merck Serono and honoraria or consultation fees from Biogen, Teva, Bayer Schering and Merck Serono. He declared also to be a member of Biogen and Teva advisory boards, board of directors or other similar groups.

Roland S. Liblau: Declared receipt of contract from Biogen Idec for detection in France of anti-natalizumab antibodies in treated patients.

Fred D. Lublin: Declared receipt of grants and contracts from Biogen, Teva, Genentech, Novartis, Acorda, Genzyme and honoraria or consultation fees from Teva, EMD Serono, Bayer, Pfizer, Genentech, Novartis, BioMS, Genmab, Actelion, Medicinova, Sanofi and Avigen. He declared also to be stakeholder in Cognition Pharma and to participate in Teva, Pfizer and EMD Serono sponsored speaker’s bureaus. His presentation will include discussion on clinical trials of agents used in early MS that have not yet received regulatory approval.

Maria Pia Sormani: Declared receipt of honoraria or consultation fees from Merck Serono, Teva and Biogen Idec.

Antonio Uccelli: Declared receipt of grants and contracts from FISM, Carige, MIUR, Italian Ministry of Health and honoraria or consultation fees from Genentech, Merck Serono, Bayer Schering, Sanofi-Aventis. He declared also to be member of Genentech advisory board, board of directors or other similar groups and participation in a Merck Serono sponsored speaker’s bureau. His presentation will contain discussion of off-label or otherwise non-approved utilization of stem cells for the treatment of MS.

Patrick Vermersch: Declared receipt of honoraria from Merck Serono for the Steering Committee for the CLARITY study.